Please assess the completion status of the following clinical trial:

Trial Title: Study of Meningococcal B Vaccine and ACWY Conjugate Vaccine in Healthy Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged 18-65 years of age~* Who have given written informed consent after the nature of the study has been explained.~* Who work within the Manchester Medical Microbiology Partnership and may be at potential occupational exposure to meningococci.~Exclusion Criteria:~* The possibility of pregnancy~* A serious chronic disease including progressive neurological disease or seizure disorder.~* Have a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.~* Have a history of severe allergic reactions after previous vaccinations such as anaphylactic shock, asthma, urticaria, or other allergic reaction or hypersensitivity to any vaccine component.~* Have received another investigational agent within 90 days or before completion of the safety follow-up period in another study, whichever is longer, prior to enrollment and unwilling to refuse participation in another investigational trial through the end of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).